Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLAS-INH: Fitusiran prophylaxis in hemophilia A or B with inhibitors
jRCT2080224128Phase 3Completed
- Sponsor
- Sanofi
- Start
- Nov 2018
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 3, randomised trial of fitusiran in hemophilia A and hemophilia B (HB) (2 arms), sponsored by Sanofi. Primary endpoints: Annualized bleeding rate during efficacy period and Annualized bleeding rate during overall treatment period. Started Nov 2018; status: completed.
02
Drugs
fitusiran
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on jRCT2080224128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224128.